C3 and paroxysmal nocturnal hemoglobinuria: Pegcetacoplan, a C3 inhibitor of the compstatin family (22), marked the second inhibitor class for PNH therapy, whereas the anti-C1s antibody sutimlimab (23) is used for treatment of CAD.